Healthcare AI Co. Rebrands to Find Massive Healthcare Market Opportunity

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI.
2. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
4. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc., the company noted in an August 18 release.

The new name was effective and began trading on the Canadian Securities Exchange under the ticker AIDR last week.

The move merges the GLM with Rocket Doctor Inc.'s leading digital health platform, aiming to provide scalable, AI-enhanced clinical and diagnostic tools. By utilizing large language models, connected medical devices, and proprietary software, the company seeks to improve healthcare access for rural, remote, and underserved communities across North America.

The move builds on the successful acquisition of Rocket Doctor Inc. in April 2025, marking a crucial step toward commercialization and delivering measurable value to patients, providers, and shareholders.

"We are very excited about this next chapter for the company," Treatment.com AI Chief Executive Officer Dr. Essam Hamza said before the change. "This name change marks a natural step in uniting our technology and service offerings under a single, stronger identity. Following the acquisition of Rocket Doctor, we are at an important inflection point. As we move toward the next phase of commercialization and prepare for our Q2 announcement, we remain focused on delivering practical; AI driven; clinically validated; scalable solutions and keeping our shareholders informed of our progress."

The new name signifies the integration of the GLM with Rocket Doctor, which is a prominent digital health platform that enables physicians to practice independently and provide comprehensive care while connecting them to patients across North America, including rural and remote communities in Canada and Medicaid and Medicare patients in the United States. This is achieved through large language models, Bluetooth medical devices, and proprietary software.

The new stock symbol, AIDR, is intended to better reflect the company's core focus on AI-driven administrative, diagnostic, clinical decision support, and referral solutions that empower healthcare professionals and patients alike.

Dr. William Cherniak, CEO of Rocket Doctor, noted at the time of the acquisition, "It's been a fast-paced journey since joining the team at Treatment.com AI. We couldn't be more thrilled to take the ethos and brand brought from our work across North America to now jointly power Rocket Doctor AI. There's much more to go in our work of improving physicians' practice of medicine, while in parallel increasing access to care for patients in need; this refined name makes clear our focus on technology as a critical component to achieving these objectives."

AI Engine Developed by Hundreds of Professionals

With input from hundreds of healthcare professionals globally, Treatment.com AI developed a comprehensive, personalized healthcare AI engine, the GLM. With over 10,000 expert medical reviews, the GLM provides tested clinical information and support to healthcare professionals, as well as recommended tests (physical and lab), imaging, and billing codes. The GLM helps healthcare professionals (doctors, nurses, or pharmacists) reduce their administrative burden, create more time for necessary face-to-face patient appointments, and ensure greater consistency in the quality of patient support.

Now Rocket Doctor Inc., has introduced a new virtual health screening program for adults over 60 in partnership with EngageWell IPA. This initiative, called the Healthy Aging Program, is supported by a five-year, US$1 million grant from the CVS Health Foundation and aims to enhance healthcare access for older adults in New York City. The program offers free virtual screenings for heart health, cognitive and memory function, and mental health.

Board-certified physicians conduct consultations via phone or video and provide personalized follow-up care plans. Community Health Workers assist participants in navigating and accessing necessary local services. Medicaid patients can use the service at no cost, while Medicare patients are covered through insurance.

Analyst: 'Shopify for Physicians'

*On May 21, Technical Analyst Clive Maund released an evaluation of Treatment.com AI Inc., emphasizing the company's strategic placement within the rapidly changing artificial intelligence (AI) healthcare sector.

Maund pointed out that the company has crafted a platform designed by physicians to tackle inefficiencies in healthcare by integrating clinical intelligence, virtual care features, and voice assistant technology into a cohesive system. He highlighted the company's diagnostic tools as providing continuous availability and AI-driven voice interactivity to aid clinical workflows.

He also likened Rocket Doctor to a "Shopify for physicians," which enables practitioners to set up remote clinics and broaden access to virtual care. Maund noted the model's scalability as a key factor in its significance to the wider telehealth market.

From a technical perspective, Maund observed that the company's stock had recently completed what he interpreted as a three-wave A-B-C correction pattern and was beginning to rise from a long-term base established over a 30-month period. He identified technical support levels that, in his opinion, indicated a potential turning point for the stock's movement. In his analysis, Maund stated that recent volume patterns indicated increasing investor interest, describing the accumulation since early 2024 as "supportive of a significant new uptrend." He outlined an initial target range of CA$1.08 to CA$1.12, with a secondary target of CA$4.00. Maund concluded that the combination of market positioning and technical indicators suggested, in his view, that it was "an excellent time to buy or add to positions."

The Catalyst: Telehealth Major Part of Last 5 Years

The virtual care and telehealth sector remained in a period of transition during mid-2025, as stakeholders navigated increasing regulatory pressures, operational scrutiny, and efforts to redefine ethical practices across the industry.

On April 3, Fierce Healthcare published a retrospective analysis examining how the COVID-19 pandemic reshaped healthcare delivery in the United States.

Jesse Ehrenfeld, M.D., immediate past president of the American Medical Association, emphasized that "you can't have a conversation about the last five years and not talk about telehealth."

He noted a dramatic rise in adoption, with three-quarters of physicians offering telehealth by late 2023, compared to only one-quarter before the pandemic. Fierce Healthcare reported that this expansion improved access to care, especially for mental health services and patients in remote areas and encouraged broader use of patient portals. However, experts like Patricia McGaffigan of the Institute for Healthcare Improvement advised that adoption must remain measured, stating, "it's important for us to proceed with a reasonable level of enthusiasm, but also a clear degree of caution."

The introduction of artificial intelligence tools into telehealth also has drawn attention.

According to Ehrenfeld, "AI is coming into practice in a way that is really exciting," citing a 78% increase in physician usage of health-related AI tools from 2023 to 2024. Yet, regulatory gaps and concerns around responsible implementation continued. Fierce Healthcare noted that general-purpose AI models were sometimes used for clinical decisions, raising questions about patient safety and oversight.

According to a June 12 report from Future Market Insights, the global wireless healthcare asset management market was projected to increase from US$52.06 billion in 2025 to US$155.40 billion by 2035. The report attributed this growth to the widespread adoption of artificial intelligence (AI), Internet of Things (IoT), and real-time tracking tools within hospitals.

These technologies were used to monitor high-value equipment such as infusion pumps and surgical instruments, improve maintenance scheduling, and enhance patient safety through predictive analytics. The report also noted that cloud-based platforms enabled real-time equipment monitoring, predictive maintenance, and compliance tracking. It identified a trend toward integrating AI systems with electronic health records (EHRs) and hospital information systems (HIS) to support resource optimization and more informed clinical decisions.

Ownership and Share Structure

According to Refinitiv, insiders own approximately 5% of the newly branded Rocket Doctor AI. Institutions nearly 1%. Retail investors own the remaining 94%.    

The company has 75.59 million outstanding common shares.  The market cap is approximately CA$45.08 million.

Over the past 52 weeks, the company traded between CA$0.33 and CA$0.85 per share.